Advances in Uveal Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 138
Special Issue Editors
Interests: uveal melanoma; cancer immunology; immunotherapy; liver-directed treatment; tumor microenvironment; mouse models
Special Issues, Collections and Topics in MDPI journals
Interests: uveal melanoma; cancer immunology; immunotherapy; tumor microenvironment; mouse models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Uveal melanoma (UM) is a rare form of melanoma, accounting for approximately 5% of all melanoma cases in the United States. Despite successful treatments of primary UM, up to 50% of UM patients subsequently develop systemic metastases, which spread predominantly to the liver.
Over the last decade, major discoveries have been made in the field of UM, including the identification of Gαq/11 mutations as driver mutations and BAP1 and SF3B1 mutations as epigenetic determinants. Advances in technology also resulted in two treatments being approved by the US FDA, namely T-cell engager, tebemtafusp-tebn (Kimmtrak™), and percutaneous hepatic perfusion with HEPZATO KIT™ (melphalan for injection/hepatic delivery system). These approaches totally changed the landscape of treatment for metastatic uveal melanoma (MUM).
In this Special Issue, we aim to envision the current status of our understanding of UM and discuss the future directions of translational research projects. We hope that this Special Issue will guide researchers in the field of UM to identify a curative approach for MUM patients.
Prof. Dr. Takami Sato
Dr. Mizue Terai
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- eye cancer
- liver metastasis
- Gαq/11 mutations
- BAP1
- SF3B1
- PRAME
- dormancy
- liver-directed treatment
- T-cell engager
